Oltmans Curtis Gale Form 4 January 23, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * Oltmans Curtis Gale

2. Issuer Name and Ticker or Trading

Symbol

ARRAY BIOPHARMA INC

[ARRY]

3. Date of Earliest Transaction

01/18/2019

(Month/Day/Year)

Director 10% Owner Officer (give title Other (specify

5. Relationship of Reporting Person(s) to

(Check all applicable)

below) General Counsel

C/O ARRAY BIOPHARMA, 3200 WALNUT ST.

(State)

(First)

(Middle)

(Zip)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

BOULDER, CO 80301

	Tuble 1 Ton Berryanye securines required, Bisposed of, or Beneficiary 6 whea								
2. Transaction Date	2A. Deemed	3.	4. Securi	ities A	cquired	5. Amount of	6. Ownership	7. Nature of	
(Month/Day/Year)	Execution Date, if	Transactio	ction(A) or Disposed of			Securities	Form: Direct	Indirect	
	any	Code	(D)			Beneficially	(D) or	Beneficial	
	(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)			Owned	Indirect (I)	Ownership	
	• •				Following	(Instr. 4)	(Instr. 4)		
						Reported			
						Transaction(s)			
		G 1 17			ъ.	(Instr. 3 and 4)			
		Code V	Amount	(D)	Price				
01/18/2010		М	1 251	٨	\$	5 172	D		
01/10/2017		171	1,231	А	8.94	3,172	D		
01/18/2010		$\mathbf{C}(1)$	1 251	D	\$ 18	3 021	D		
01/10/2019		5 <u>~</u>	1,431	ט	ψ10	3,741	D		
		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 01/18/2019	2. Transaction Date 2A. Deemed 3. Transaction Date if any (Month/Day/Year) (Month/Day/Year) Code (Instr. 8) Code V 01/18/2019 M	2. Transaction Date (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) Code (D) (Instr. 8) (Instr. 3, 4. Securion Date, if any (Code (D)) (Month/Day/Year) Code V Amount M 1,251	2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) or Code V Amount (D) O1/18/2019 M 1,251 A	2. Transaction Date (Month/Day/Year) 2A. Deemed 3. 4. Securities Acquired Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price M 1,251 A \$8.94	2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) Owned Following Reported Transaction(s) (Instr. 3 and 4) (Instr. 3 and 4) (Instr. 3 and 4)	2. Transaction Date (Month/Day/Year) 2A. Deemed 3. 4. Securities Acquired (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Code (D) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) (Instr. 4) (Instr. 3) (Instr. 3)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Oltmans Curtis Gale - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

8. I De Sec (In

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number out of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 8.94	01/18/2019		M	1,251	(2)	08/15/2027	Common Stock	1,251

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Oltmans Curtis Gale

C/O ARRAY BIOPHARMA, 3200 WALNUT ST. General Counsel

BOULDER, CO 80301

Signatures

Jason Haddock, attorney-in-fact for Curtis
Oltmans
01/23/2019

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These trades were made pursuant to a Rule 10b5-1 trading plan.
- (2) The option vests in four equal annual installments beginning August 15, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2